Fms-related tyrosine kinase 3 ligand (FLT3LG) is a protein which in humans is encoded by the FLT3LG gene. (wikipedia.org)
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Mouse FMS Like Tyrosine Kinase 3 Ligand (Flt3L) in serum, plasma and other biological fluids. (fslregister.nl)
Description: A sandwich ELISA kit for detection of FMS Like Tyrosine Kinase 3 Ligand from Mouse in samples from blood, serum, plasma, cell culture fluid and other biological fluids. (fslregister.nl)
Description: This is Double-antibody Sandwich Chemiluminescent immunoassay for detection of Mouse FMS Like Tyrosine Kinase 3 Ligand (Flt3L) in serum, plasma and other biological fluids. (fslregister.nl)
Background: Fms-like tyrosine kinase-3 ligand (Flt3L) is a hemopoietic cytokine and dendritic cell (DC) growth factor that promotes the proliferation and differentiation of progenitor cells into DCs. (utmb.edu)
Bohannon, JK, Cui, W & Toliver-Kinsky, T 2009, ' Endogenous Fms-like tyrosine kinase-3 ligand levels are not altered in mice after a severe burn and infection ', BMC Immunology , vol. 10, 1471, pp. 47. (utmb.edu)
Flt-3 Ligand, also known as FL, is an alpha-helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages. (rndsystems.com)
Mature human Flt-3 Ligand consists of a 158 amino acid (aa) extracellular domain (ECD) with a cytokine-like domain and a juxtamembrane tether region, a 21 aa transmembrane segment, and a 30 aa cytoplasmic tail. (rndsystems.com)
Within the ECD, human Flt-3 Ligand shares 71% and 65% aa sequence identity with mouse and rat Flt-3 Ligand, respectively. (rndsystems.com)
Human and mouse Flt-3 Ligand show cross-species activity. (rndsystems.com)
Flt-3 Ligand is expressed as a noncovalently-linked dimer by T cells and bone marrow and thymic fibroblasts. (rndsystems.com)
Alternate splicing of human Flt-3 Ligand also generates membrane-associated isoforms that contain either a truncated cytoplasmic tail or an 85 aa substitution following the cytokine domain. (rndsystems.com)
Both transmembrane and soluble Flt-3 Ligand signal through the tyrosine kinase receptor Flt-3/Flk-2. (rndsystems.com)
Flt-3 Ligand induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation. (rndsystems.com)
Animal studies also show Flt-3 Ligand to reduce the severity of experimentally induced allergic inflammation. (rndsystems.com)
Be the first to review Cyno Monkey Flt-3 Ligand (XP_005589968.1) VersaClone cDNA and earn rewards! (rndsystems.com)
CD135, also known as FMS-like tyrosine kinase-3, FLT3, STK-1, and Flk-2, is a growth factor receptor that binds the FLT3 ligand to promote the growth and differentiation of primitive hematopoietic cells. (biolegend.com)
Western blot analysis of extracts from BaF3/FLT3 cells, untreated or stimulated with FLT3 Ligand (FL) (3 µg/ml for 5 minutes), using Phospho-FLT3 (Tyr591) Antibody (upper) or FLT3 (8F2) Rabbit mAb #3462 antibody (lower). (cellsignal.com)
GTP-14564 inhibited the growth of interleukin-3-independent Ba/F3 expressing ITD-FLT3 at 1 μM, whereas a 30-fold higher concentration of GTP-14564 was required to inhibit FLT3 ligand-dependent growth of Ba/F3 expressing wild type FLT3 (wt-FLT3). (elsevierpure.com)
Not shown here is the activation under certain conditions of Jaks that are bound to some G-protein-coupled receptors (GPCRs) and the phosphorylation of STATs directly by certain ligand-activated growth factor receptors (RTKs) as well as non-receptor tyrosine kinases. (shu.edu)
Mutations in the tyrosine kinase, whether in BCR-ABL in CML or a FLT3 mutation in AML, bypass control that comes from ligand binding. (shu.edu)
For expansion, Pro-B cells were cultured on OP9 stromal cells supplemented with 10ng/mL KIT ligand, 10ng/mL Fms-like tyrosine kinase 3 ligand (FLT3L), and 10ng/mL Interleukin-7 in Optimem supplemented with 10% FCS, Beta-mercaptoethanol, HEPES and Penstrep. (nih.gov)
Cellular Basis for the Enhanced Efficacy of the Fms-Like Tyrosine Kinase 3 Ligand (FL) Adjuvanted VCG-Based Chlamydia abortus Vaccine. (cdc.gov)
In this study, we investigated the immunomodulatory effect of the hematopoietic progenitor activator cytokine, Fms-like tyrosine kinase 3-ligand (FL) when co-administered with the rVCG-Pmp18.1 vaccine as a strategy to enhance the protective efficacy and the potential mechanism of immunomodulation. (cdc.gov)
Inhibitor9
3 , 4 Since 2020, older or unfit patients are treated by a non-intensive approach combining the hypomethylating agent azacitidine and the B-cell lymphoma 2 (BCL2) inhibitor venetoclax given orally until progression. (dovepress.com)
FLT3ITD/NFATC1-AML is transplantable in sub-lethally irradiated WT recipients and confers resistance to the FLT3ITD-kinase inhibitor quizartinib. (uni-marburg.de)
Turalio (pexidartinib) is a kinase inhibitor indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. (rxlist.com)
In this stcudy, we identified GTP-14564 as a specific kinase inhibitor for ITD-FLT3 and investigated the molecular basis of its specificity. (elsevierpure.com)
However, this inhibitor suppressed the kinase activities of wt-FLT3 and ITD-FLT3 equally, suggesting that the signaling pathways for proliferation differ between wt-FLT3 and ITD-FLT3. (elsevierpure.com)
Sorafenib is available in 200-mg tablets for oral administrationand is used in the treatment of RCC and colon cancer.The agent is classified as a multikinase inhibitor because ofits action on numerous kinase enzymes including thePDGF-R, VEGF-R, Kit, and Raf. (guidechem.com)
Sorafenib Tosylate (Bay 43-9006, Nexavar) is a small molecular inhibitor of VEGFR, PDGFR, c-Raf and B-Raf with IC50s of 18 nM, 10 nM, 3 nM and 15 nM, respectively. (guidechem.com)
Quizartinib is an oral, selective type II FMS-like tyrosine kinase 3 (FLT3) inhibitor for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation. (primetherapeutics.com)
Mutations5
Among activating class III receptor tyrosine kinase (Flt3) mutations, internal tandem duplications of Flt3 (Flt3-ITD) are detected in about 25% of patients with acute myeloid leukemia (AML). (nih.gov)
In contrast, mutations within the tyrosine kinase domain of Flt3 (Flt3-TKD mutations) are less frequent (approximately 7%), and there are only limited data on the frequency of recently demonstrated activating Flt3 point mutation at codon 592 (Flt3-V592A mutation). (nih.gov)
We identified 9 cases (8%) of Flt3-TKD mutations (5 cases of mutation D835Y, 3 cases of mutation D835H, and 1 case of mutation Del836), and no cases of Flt3-V592A mutation. (nih.gov)
BACKGROUND: The impact of single versus multiple fms-like tyrosine kinase receptor 3 internal tandem duplication (FLT3-ITD) mutations on the clinical outcome of patients with acute myelogenous leukemia has not been well studied, and particularly has not been investigated while simultaneously accounting for the quantitative mutation burden. (elsevierpure.com)
The treatment paradigm of AML patients harboring FLT3 mutations (30%) has been modified by the discovery of tyrosine kinase inhibitors. (dovepress.com)
Tandem4
Approximately 30% of the adult cases harbor an internal tandem duplication ( FLT3 -ITD) and 5- 10% a tyrosine kinase domain (TKD) amino acid substitution ( FLT3-TKD ). (dovepress.com)
Till now, the medicines approved for acute myeloid leukemia with internal tandem duplication mutation of FMS-like tyrosine kinase 3 (FLT3-ITD) display not ideal efficacy. (banglajol.info)
Internal tandem duplication ITD-mutated FMS-like Tyrosine Kinase-3 (FLT3) is associated with poor prognosis in patients with acute myeloid leukemia (AML). (uni-marburg.de)
The receptor tyrosine kinase FLT3 is constitutively activated by an internal tandem duplication (ITD) mutation within the juxtamembrane domain in 20-30% of patients with acute myeloid leukemia. (elsevierpure.com)
Inhibitors9
Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed. (tu-darmstadt.de)
Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia. (tu-darmstadt.de)
Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds. (tu-darmstadt.de)
FMS-Like Tyrosine kinase 3 (FLT3) inhibitors market size was USD 405.6 Million in 2021 and is expected to register a revenue CAGR of 14.6% during the forecast period, according to latest analysis by Emergen Research. (meerutreporter.com)
The Global FMS Like Tyrosine kinase 3 Inhibitors Market Report offers extensive knowledge and information about the FMS Like Tyrosine kinase 3 Inhibitors market pertaining to market size, market share, growth influencing factors, opportunities, and current and emerging trends. (meerutreporter.com)
The report is formulated with the updated and latest information of the global FMS Like Tyrosine kinase 3 Inhibitors market further validated and verified by the industry experts and professionals. (meerutreporter.com)
The Global FMS Like Tyrosine kinase 3 Inhibitors Market report contains historical, current, and forecast estimation of the revenue generation and profits for each segment and sub-segment of the FMS Like Tyrosine kinase 3 Inhibitors market in each key region of the world. (meerutreporter.com)
The report discusses in detail the growth opportunities, challenges, market drivers and restraints, limitations, threats, and demands of the FMS Like Tyrosine kinase 3 Inhibitors market. (meerutreporter.com)
The report also provides deeper insights into the technological advancements, industrial landscape, and emerging product and technological developments in the FMS Like Tyrosine kinase 3 Inhibitors market. (meerutreporter.com)
Soluble2
OBJECTIVE: To evaluate the clinical significance of soluble fms-like tyrosine kinase1 (sFlt-1), soluble endoglin (sEng) and placental growth factor (PlGF) in preeclampsia. (koreamed.org)
In intact cells, including primary AML cells, FLT3 ITD kinase inhibition reactivated DEP-1. (nih.gov)
FLT3 (FMS-related tyrosine kinase 3) located on chromosome 13q12.2 encodes a receptor tyrosine kinase (RTK) that activates the Ras and PI3 kinase pathway leading to the increased proliferation and inhibition of apoptosis in hemopoietic progenitor cells [ 7 ]. (hindawi.com)
Protein2
Signal transduction of FMS-like tyrosine kinase 3 (FLT3) is regulated by protein-tyrosine phosphatases (PTPs). (nih.gov)
CD31 (platelet endothelial cell adhesion molecule-1, PECAM-1) is an inhibitory coreceptor involved in regulation of T cell and B cell signaling by a dual immunoreceptor tyrosine-based inhibitory motif (ITIM) that upon associated kinases-mediated phosphorylation provide docking sites for protein-tyrosine phosphatases. (thermofisher.com)
CD1351
CD135 is a 130-160 kD type III tyrosine kinase receptor expressed on CD34 + hematopoietic stem cells, myelomonocytic progenitors, primitive B cell progenitors, and thymocytes. (biolegend.com)
Acute myeloid1
FMS-like tyrosine kinase 3 ( FLT3 ) is one of the most frequently mutated genes in acute myeloid leukemia (AML). (dovepress.com)
Antibody1
The FDA has granted priority review to UCB's rozanolixizumab for treatment of adults with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. (primetherapeutics.com)
Mutation1
Examples of MRD analyses are presented for all 3 subtypes of Flt3-TKD mutation identified in this study. (nih.gov)
Quizartinib1
Quizartinib is seeking approval based on the Phase 3 QuANTUM-First study that achieved a statistically significant overall survival (OS) rate. (primetherapeutics.com)
Pathway1
The Jak-STAT pathway The Jak-STAT pathway depends upon the actions of Jak tyrosine kinases (for example, Jak1, Tyk2), which are attached noncovalently to a number of cytokine receptors, including those for interferons, erythropoietin (EPO), and thrombopoietin (TPO). (shu.edu)
Clinical2
Although a coagulation profile (prothrombin time [PT], activated partial thromboplastin time [aPTT], and fibrinogen) should also be evaluated, its clinical value is unclear when the platelet count is 100,000/mm 3 or more with no evidence of bleeding. (medscape.com)
3 - 7 The synergistic effect of BCL2 and MYC has also been implicated in the histological and clinical transformation of indolent follicular lymphoma into a more aggressive lymphoma. (haematologica.org)
Hematopoietic1
It synergizes with IL-3, GM-CSF, and SCF to promote the mobilization and myeloid differentiation of hematopoietic stem cells. (rndsystems.com)
FLT3 ( FMS -related tyrosine kinase 3) acts as an oncogene in myeloid neoplasms which is associated with several signal transduction pathways. (hindawi.com)
Cells1
Transferred T cells that persist in the blood and form memory have a phenotype consistent with a less differentiated state (CD27/CD28/IL-7 receptor-α) [ 3 ]. (biomedcentral.com)
Further analysis demonstrated that the first two tyrosines in an ITD were critical for STAT5 activation and growth induction but that all of the tyrosines in the juxtamembrane region were dispensable in terms of the proliferation signals of wt-FLT3. (elsevierpure.com)
Poor prognosis2
The presence of dmin often correlates with a poor prognosis in tumors [ 3 ]. (hindawi.com)
Patients with resistant or relapsed (r/r) DLBCL have a poor prognosis with a median overall survival of 6,3 months and low complete response rates (CR 7%) to salvage chemoimmunotherapy. (deepdyve.com)
Journal1
To further explore whether the presence of urinary podocyte shedding would predict the onset of preeclampsia, a study published in the journal Hypertension in 2013 looked at 3 groups of women, all of whom were followed prospectively from their initial clinic visit. (medscape.com)
Cell1
It cooperates with IL-2, -6, -7, and -15 to induce NK cell development and with IL-3, -7, and -11 to induce terminal B cell maturation. (rndsystems.com)
Phase2
Beyfortus is seeking approval based on data including the MELODY Phase 3, MEDLEY Phase 2/3, and Phase 2b trials. (primetherapeutics.com)
Verrica Pharmaceuticals is seeking FDA approval based on the Phase 3 CAMP trial that demonstrated Ycanth to be statistically significant when compared to placebo. (primetherapeutics.com)
Study1
The researchers matched in a 3:1 ratio normotensive controls (n=44) against patients with gestational hypertension (n=15) and the study group who eventually developed preeclampsia (n=15). (medscape.com)
Treatment1
1-3 Current treatment cures only a minority of AML patients and less than 20% have a long-term survival. (dovepress.com)